

Antipsychotic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others), By Drug Classification (First Generation (Typical), Second Generation (Atypical)), By Region and Competition, 2020-2030F

<https://marketpublishers.com/r/AB73DD589B11EN.html>

Date: May 2025

Pages: 185

Price: US\$ 4,500.00 (Single User License)

ID: AB73DD589B11EN

Abstracts

Market Overview

The Global Antipsychotic Drugs Market was valued at USD 15.29 billion in 2024 and is projected to reach USD 25.48 billion by 2030, expanding at a CAGR of 8.88% during the forecast period. This market serves as a vital component of the pharmaceutical sector, addressing serious mental health disorders such as schizophrenia, bipolar disorder, and treatment-resistant depression. Antipsychotic medications, also known as neuroleptics, are designed to manage and reduce symptoms like hallucinations, delusions, and mood instability by targeting neurotransmitter imbalances, primarily dopamine, in the brain. With mental health conditions on the rise globally, fueled by societal stressors and lifestyle changes, demand for these drugs is escalating. According to the World Health Organization, nearly one in eight people worldwide were living with a mental disorder in 2019. The COVID-19 pandemic further intensified this trend, with significant increases in cases of anxiety and depression. As awareness grows and stigmas diminish, more individuals are seeking treatment, contributing to market expansion. Antipsychotics continue to evolve, offering improved efficacy and tolerability, and playing a key role in long-term psychiatric care and quality-of-life improvement for affected patients.

Key Market Drivers

Rising Prevalence of Mental Health Disorders

The increasing global incidence of psychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder is a primary growth driver for the antipsychotic drugs market. This rise is attributed to various factors including changing lifestyles, heightened stress levels, and improved diagnostic capabilities. Greater public awareness and reduced stigma around mental health are prompting more individuals to seek professional care. Consequently, this has led to higher diagnosis rates and an expanding patient population requiring pharmaceutical intervention.

Antipsychotic drugs are essential in managing severe mental health symptoms, stabilizing patients, and preventing relapses. Their role in enhancing daily functioning and overall well-being has become increasingly prominent, aligning with the growing focus on holistic mental healthcare.

Key Market Challenges

Adverse Side Effects

A major challenge for the antipsychotic drugs market is the prevalence of adverse effects associated with these medications. Despite the advancements seen with second-generation (atypical) antipsychotics, many patients still experience side effects including significant weight gain, metabolic syndrome, sedation, and sexual dysfunction. These complications can hinder treatment adherence and diminish quality of life. Managing such side effects often requires additional medical oversight and therapeutic adjustments, which can increase healthcare costs and complicate patient care. This challenge underscores the importance of developing newer antipsychotic formulations with improved safety profiles to enhance patient compliance and long-term treatment outcomes.

Key Market Trends

Personalized Medicine Approach

The shift towards personalized medicine is a notable trend shaping the future of the antipsychotic drugs market. Leveraging pharmacogenomics, clinicians are now tailoring treatments to individual genetic profiles, enabling the selection of the most appropriate drug and dosage for each patient. This customized approach minimizes the

risk of adverse effects and improves therapeutic efficacy. The integration of genetic testing and data-driven decision-making is helping to move beyond the traditional trial-and-error model, enhancing both clinical outcomes and patient satisfaction. As healthcare systems globally prioritize individualized care, personalized antipsychotic treatment strategies are expected to become a cornerstone in psychiatric therapy.

Key Market Players

Eli Lilly and Company

AstraZeneca plc

GlaxoSmithKline plc

Johnson & Johnson

Otsuka Pharmaceutical Co., Ltd.

Pfizer Inc.

AbbVie Inc.

Dr. Reddy's Laboratories Limited

Otsuka Holdings Co., Ltd.

Teva Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Antipsychotic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antipsychotic Drugs Market, By Application:

Schizophrenia

Bipolar Disorder

Unipolar Disorder

Dementia

Others

Antipsychotic Drugs Market, By Drug Classification:

First Generation (Typical)

Second Generation (Atypical)

Antipsychotic Drugs Market, By Region:

North America

United States

Mexico

Canada

Europe

France

Germany

United Kingdom

Italy

Spain

Asia-Pacific

China

India

South Korea

Japan

Australia

South America

Brazil

Argentina

Colombia

Middle East and Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antipsychotic Drugs Market.

Available Customizations:

Global Antipsychotic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others)
 - 5.2.2. By Drug Classification (First Generation (Typical), Second Generation (Atypical))
 - 5.2.3. By Company (2024)

- 5.2.4. By Region
- 5.3. Market Map

6. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Application
 - 6.2.2. By Drug Classification
 - 6.2.3. By Country
- 6.3. North America: Country Analysis
 - 6.3.1. United States Antipsychotic Drugs Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Application
 - 6.3.1.2.2. By Drug Classification
 - 6.3.2. Mexico Antipsychotic Drugs Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Application
 - 6.3.2.2.2. By Drug Classification
 - 6.3.3. Canada Antipsychotic Drugs Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Application
 - 6.3.3.2.2. By Drug Classification

7. EUROPE ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Application
 - 7.2.2. By Drug Classification
 - 7.2.3. By Country

7.3. Europe: Country Analysis

7.3.1. France Antipsychotic Drugs Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Application

7.3.1.2.2. By Drug Classification

7.3.2. Germany Antipsychotic Drugs Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Application

7.3.2.2.2. By Drug Classification

7.3.3. United Kingdom Antipsychotic Drugs Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Application

7.3.3.2.2. By Drug Classification

7.3.4. Italy Antipsychotic Drugs Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Application

7.3.4.2.2. By Drug Classification

7.3.5. Spain Antipsychotic Drugs Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Application

7.3.5.2.2. By Drug Classification

8. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Application

8.2.2. By Drug Classification

8.2.3. By Country

8.3. Asia-Pacific: Country Analysis

8.3.1. China Antipsychotic Drugs Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Application

8.3.1.2.2. By Drug Classification

8.3.2. India Antipsychotic Drugs Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Application

8.3.2.2.2. By Drug Classification

8.3.3. South Korea Antipsychotic Drugs Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Application

8.3.3.2.2. By Drug Classification

8.3.4. Japan Antipsychotic Drugs Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Application

8.3.4.2.2. By Drug Classification

8.3.5. Australia Antipsychotic Drugs Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Application

8.3.5.2.2. By Drug Classification

9. SOUTH AMERICA ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Application

- 9.2.2. By Drug Classification
- 9.2.3. By Country
- 9.3. South America: Country Analysis
 - 9.3.1. Brazil Antipsychotic Drugs Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Application
 - 9.3.1.2.2. By Drug Classification
 - 9.3.2. Argentina Antipsychotic Drugs Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Application
 - 9.3.2.2.2. By Drug Classification
 - 9.3.3. Colombia Antipsychotic Drugs Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Application
 - 9.3.3.2.2. By Drug Classification

10. MIDDLE EAST AND AFRICA ANTIPSYCHOTIC DRUGS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Application
 - 10.2.2. By Drug Classification
 - 10.2.3. By Country
- 10.3. MEA: Country Analysis
 - 10.3.1. South Africa Antipsychotic Drugs Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value
 - 10.3.1.2. Market Share & Forecast
 - 10.3.1.2.1. By Application
 - 10.3.1.2.2. By Drug Classification
 - 10.3.2. Saudi Arabia Antipsychotic Drugs Market Outlook
 - 10.3.2.1. Market Size & Forecast

- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
 - 10.3.2.2.1. By Application
 - 10.3.2.2.2. By Drug Classification
- 10.3.3. UAE Antipsychotic Drugs Market Outlook
 - 10.3.3.1. Market Size & Forecast
 - 10.3.3.1.1. By Value
 - 10.3.3.2. Market Share & Forecast
 - 10.3.3.2.1. By Application
 - 10.3.3.2.2. By Drug Classification

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

13. PESTLE ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product

15. COMPETITIVE LANDSCAPE

- 15.1. Eli Lilly and Company
 - 15.1.1. Business Overview
 - 15.1.2. Company Snapshot
 - 15.1.3. Products & Services
 - 15.1.4. Financials (As Reported)

- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. AstraZeneca plc
- 15.3. GlaxoSmithKline plc
- 15.4. Johnson & Johnson
- 15.5. Otsuka Pharmaceutical Co, Ltd.
- 15.6. Pfizer Inc.
- 15.7. AbbVie Inc.
- 15.8. Dr. Reddy's Laboratories Limited
- 15.9. Otsuka Holdings Co., Ltd.
- 15.10. Teva Pharmaceutical Industries Ltd.

16. STRATEGIC RECOMMENDATION

17. ABOUT US & DISCLAIMER

I would like to order

Product name: Antipsychotic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Schizophrenia, Bipolar Disorder, Unipolar Disorder, Dementia, Others), By Drug Classification (First Generation (Typical), Second Generation (Atypical)), By Region and Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/AB73DD589B11EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB73DD589B11EN.html>